While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

The diabetes medicine Ozempic has been a veritable cash cow for Novo Nordisk (NYSE: NVO). The company's revenue, earnings, and stock price have been on a tear in recent years -- and no single drug ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages. Nestlé's new food line ...

Medications used for weight loss, such as Ozempic, Wegovy ... invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock ...

That, coupled with skyrocketing usage and supply chain issues, has hindered the stock of both medicines. And of course, there is also the insurance factor — most health plans will cover Ozempic ...

Embecta Corp. focuses on diabetes products and recently received FDA approval for a new patch pump. Read why I'm neutral on ...

This extension is one of the fifth-letter identifiers that appear after a dot and a company’s ticker symbol. It indicates that the stock differs from single issues of common or capital stock.

Should you sell the healthcare stock? No reason to hit the panic button Regulatory authorities are already aware of the potential association between Ozempic -- or at least its active ingredient ...